Print Friendly

All E-Alerts

E-Alerts

FDA Warns Tofacitinib (XELJANZ, XELJANZ XR) Increases Risk of Serious Heart-Related Adverse Effects and Cancer (March 1, 2021)
FDA Warns Against Using NSAIDs in Pregnancy at 20 Weeks or Later (November 16, 2020)
FDA Warns Consumers Not to Use Dangerous Black Salve or Similar Products (October 15, 2020)
FDA Warns of Serious Breathing Problems with Use of Seizure and Nerve Pain Medications Gabapentin and Pregabalin (January 30, 2020)
FDA Announces Discovery of Cancer-Causing Contaminant in Heartburn Medication (September 20, 2019)
Foreign Regulators Act After Evidence of Harm for Fetuses of Women Users of Wakefulness Drugs Armodafinil (NUVIGIL) and Modafinil (PROVIGIL) (June 27, 2019)
FDA Warns Women of Childbearing Age Not to Take Dietary Supplements Containing Vinpocetine (June 11, 2019)
FDA Warns of Life-Threatening Blood Clots With Use of High-Dose Tofacitinib (XELJANZ, XELJANZ XR) (March 6, 2019)
FDA Announces Recalls of Certain Valsartan-Containing Medications Because of Cancer-Causing Contaminant (July 18, 2018)
FDA Announces Withdrawal of Multiple Sclerosis Drug From the U.S. Market Because of Serious Safety Concerns (March 16, 2018)

1 of 10